U.S. Markets closed

MaxCyte, Inc. (MXCT.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
900.00+8.00 (+0.90%)
At close: 5:16PM BST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close892.00
Open900.00
Bid890.00 x 0
Ask910.00 x 0
Day's Range894.85 - 910.00
52 Week Range180.50 - 1,060.00
Volume583,221
Avg. Volume98,494
Market Cap855.547M
Beta (5Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-12.30
Earnings DateApr 20, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.03
  • Proposed Dual-Listing on Nasdaq
    PR Newswire

    Proposed Dual-Listing on Nasdaq

    MaxCyte, Inc. (LSE: MXCT, MXCL, MXCN) ("MaxCyte" or the "Company"), a leading provider of platform technologies for cell engineering, today announces that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market (the "Offering").

  • MaxCyte, Inc. (LON:MXCT) Is Expected To Breakeven In The Near Future
    Simply Wall St.

    MaxCyte, Inc. (LON:MXCT) Is Expected To Breakeven In The Near Future

    We feel now is a pretty good time to analyse MaxCyte, Inc.'s ( LON:MXCT ) business as it appears the company may be on...

  • Questor: a ‘very special company’ about to list where investors will be besotted with it
    The Telegraph

    Questor: a ‘very special company’ about to list where investors will be besotted with it

    We can have no complaint about the performance of shares in MaxCyte, whose hi-tech machines help drugs firms make gene editing treatments: tipped at 370p in October last year, when we said they might be worth 500p, they closed last night at 886p and were as high as £10.40 in February. Normally we’d consider selling when a target price has been breached so comprehensively but MaxCyte finds itself in an anomalous position that it is about to rectify, a process that could do wonders for the share price. The company is based in America, has a roster of clients that are largely American and is the type of business that generates great enthusiasm among American investors – yet its shares trade on London’s Aim market. It would make far more sense to have a listing on the stock market favoured by its natural investors – the Nasdaq in New York – and the company is in the process of getting just such a listing. In the words of Richard Penny of Crux Asset Management, which owns a stake in MaxCyte, “investors in the US are besotted with gene editing – they are hugely buoyant about what they see as the third age of drug discovery” built on the decoding of the human genome 20 years ago. Besotted investors are in much shorter supply here. Britain may have a huge fund management industry but when it comes to the healthcare sector it lacks the critical mass in terms of specialist analysts, funds and brokers found in America. In fact, you could say we are positively hostile to healthcare start-ups at present. “Fire sales of the small biotech firms held in Neil Woodford’s funds depressed share prices and damaged sentiment across the board,” Mr Penny said.